These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31513035)

  • 41. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
    Krawczyk N; Picher CE; Feder KA; Saloner B
    Health Aff (Millwood); 2017 Dec; 36(12):2046-2053. PubMed ID: 29200340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 44. Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).
    D'Onofrio G; Edelman EJ; Hawk KF; Pantalon MV; Chawarski MC; Owens PH; Martel SH; VanVeldhuisen P; Oden N; Murphy SM; Huntley K; O'Connor PG; Fiellin DA
    Implement Sci; 2019 May; 14(1):48. PubMed ID: 31064390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 47. Buprenorphine Prescribing: To Expand or Not to Expand.
    Li X; Shorter D; Kosten TR
    J Psychiatr Pract; 2016 May; 22(3):183-92. PubMed ID: 27123798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.
    Stein BD; Saloner B; Schuler MS; Gurvey J; Sorbero M; Gordon AJ
    JAMA; 2021 Jun; 325(21):2206-2208. PubMed ID: 34061152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Innovations in efforts to expand treatment for opioid use disorder.
    Sigmon SC
    Prev Med; 2019 Nov; 128():105818. PubMed ID: 31445112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.
    McBain RK; Dick A; Sorbero M; Stein BD
    Ann Intern Med; 2020 Apr; 172(7):504-506. PubMed ID: 31905379
    [No Abstract]   [Full Text] [Related]  

  • 51. Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.
    Shover CL
    Psychiatr Serv; 2021 Feb; 72(2):225-226. PubMed ID: 32907476
    [No Abstract]   [Full Text] [Related]  

  • 52. Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis.
    Knudsen HK; Lin LA; Lofwall MR
    Subst Abus; 2020; 41(2):259-268. PubMed ID: 31295057
    [No Abstract]   [Full Text] [Related]  

  • 53. Projected Contributions of Nurse Practitioners and Physicians Assistant to Buprenorphine Treatment Services for Opioid Use Disorder in Rural Areas.
    Andrilla CHA; Patterson DG; Moore TE; Coulthard C; Larson EH
    Med Care Res Rev; 2020 Apr; 77(2):208-216. PubMed ID: 30089426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.
    Fox L; Nelson LS
    CNS Drugs; 2019 Dec; 33(12):1147-1154. PubMed ID: 31552608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re-purposing anticoagulation clinics: expanding access to opioid agonist therapy in primary care settings.
    Lagisetty P; Heisler M; Bohnert A
    Addiction; 2017 Mar; 112(3):384-385. PubMed ID: 27550143
    [No Abstract]   [Full Text] [Related]  

  • 56. Advanced Practice Providers and Buprenorphine Access in the United States After the Comprehensive Addiction and Recovery Act.
    Lee D; Saloner B; Barnett M
    Psychiatr Serv; 2021 Nov; 72(11):1358-1359. PubMed ID: 34734748
    [No Abstract]   [Full Text] [Related]  

  • 57. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Making Amends for the Opioid Epidemic.
    Sharfstein JM; Olsen Y
    JAMA; 2019 Apr; 321(15):1446-1447. PubMed ID: 30990541
    [No Abstract]   [Full Text] [Related]  

  • 59. In-office opiate treatment "not a panacea": physicians slow to embrace therapeutic option.
    Vastag B
    JAMA; 2003 Aug; 290(6):731-5. PubMed ID: 12915410
    [No Abstract]   [Full Text] [Related]  

  • 60. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.